Olema Pharmaceuticals (OLMA)
NASDAQ:OLMA
Want to see OLMA full AI Analyst Report?
Top Page
Olema Pharmaceuticals
(NASDAQ:OLMA)
Select Model
Select Model
Rating:47Neutral
Price Target:
$14.00
▼(-16.77% Downside)
Action:ReiteratedDate:04/30/26
Overall score is pulled down primarily by persistent, widening losses and accelerating cash burn, plus a clearly bearish technical setup (price below key moving averages and negative MACD). The main offset is a strong, low-leverage balance sheet that provides financial flexibility, but valuation is not supportive due to negative earnings and no dividend.
Positive Factors
Low-Leverage Balance Sheet
A very low debt load versus sizable equity provides durable financial flexibility for a clinical-stage biotech. It reduces near-term insolvency and interest burdens, enabling Olema to fund trials, pursue partnerships or non-dilutive options and negotiate better deal terms as programs mature.
Negative Factors
Accelerating Cash Burn
Rapidly increasing negative operating cash flow is a persistent structural risk: it raises near-term funding needs, increases dilution or debt dependence, and could force financing decisions that affect strategy or timelines while late-stage trials demand sustained capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Low-Leverage Balance Sheet
A very low debt load versus sizable equity provides durable financial flexibility for a clinical-stage biotech. It reduces near-term insolvency and interest burdens, enabling Olema to fund trials, pursue partnerships or non-dilutive options and negotiate better deal terms as programs mature.
Read all positive factors
Olema Pharmaceuticals (OLMA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.25B
Dividend YieldN/A
Average Volume (3M)1.87M
Price to Earnings (P/E)―
Beta (1Y)0.99
Revenue GrowthN/A
EPS Growth13.36%
CountryUS
Employees96
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.86
Shares Outstanding87,156,960
10 Day Avg. Volume830,600
30 Day Avg. Volume1,873,643
Financial Highlights & Ratios
PEG Ratio0.89
Price to Book (P/B)4.55
Price to Sales (P/S)0.00
P/FCF Ratio-14.83
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.90K
Enterprise Value/Ebitda-7.04
Forecast
1Y Price Target
$42.22Price Target Upside151.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.24
Revenue Forecast (FY)$2.05M
Olema Pharmaceuticals Business Overview & Revenue Model
Company Description
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and...
How the Company Makes Money
null...
Olema Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -178.21M | -141.87M | -104.58M | -106.63M | -71.33M |
| Net Income | -162.45M | -129.47M | -96.66M | -104.79M | -71.10M |
Balance Sheet | |||||
| Total Assets | 533.43M | 450.98M | 276.94M | 215.65M | 295.94M |
| Cash, Cash Equivalents and Short-Term Investments | 505.44M | 434.09M | 261.81M | 204.42M | 287.25M |
| Total Debt | 1.19M | 1.43M | 2.42M | 2.56M | 3.29M |
| Total Liabilities | 54.87M | 42.02M | 23.05M | 18.10M | 11.38M |
| Stockholders Equity | 478.56M | 408.96M | 253.90M | 197.55M | 284.57M |
Cash Flow | |||||
| Free Cash Flow | -146.72M | -104.51M | -83.73M | -82.43M | -52.27M |
| Operating Cash Flow | -146.72M | -104.35M | -83.73M | -82.06M | -50.69M |
| Investing Cash Flow | -155.76M | -93.53M | -4.85M | 91.48M | -275.44M |
| Financing Cash Flow | 211.30M | 268.82M | 133.41M | 476.00K | 1.39M |
Olema Pharmaceuticals Technical Analysis
Neutral
16.82
Price Trends
18.81
Negative
23.13
Negative
15.34
Positive
Market Momentum
-0.45
Negative
52.24
Neutral
82.03
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OLMA, the sentiment is Neutral. The current price of 16.82 is above the 20-day moving average (MA) of 15.17, below the 50-day MA of 18.81, and above the 200-day MA of 15.34, indicating a neutral trend. The MACD of -0.45 indicates Negative momentum. The RSI at 52.24 is Neutral, neither overbought nor oversold. The STOCH value of 82.03 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OLMA.
Olema Pharmaceuticals Risk Analysis
Olema Pharmaceuticals disclosed 89 risk factors in its most recent earnings report. Olema Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Olema Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $227.36M | 8.71 | 14.25% | ― | 6774.96% | ― | |
52 Neutral | $870.96M | -5.60 | 4438.87% | ― | 144.57% | 32.96% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $672.23M | -9.53 | -14.25% | ― | -0.30% | 56.14% | |
47 Neutral | $1.25B | -13.39 | -42.90% | ― | ― | 13.36% | |
46 Neutral | $352.97M | -12.74 | -43.61% | ― | -100.00% | -20.71% | |
41 Neutral | $86.79M | -3.72 | 264.70% | ― | -57.74% | -199.96% |
* Healthcare Sector Average
OLMA
Olema Pharmaceuticals
14.63
9.07
163.13%
MGTX
Meiragtx Holdings
9.70
3.25
50.39%
ARVN
Arvinas Holding Company
10.78
3.15
41.28%
GOSS
Gossamer Bio
0.35
-0.90
-72.00%
KROS
Keros Therapeutics
11.71
-2.85
-19.57%
CMPX
Compass Therapeutics
1.94
0.08
4.30%
Olema Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board Changes
Olema Pharmaceuticals Adds Veteran Director to Support Growth
Positive
Apr 29, 2026
Olema Oncology, the operating name of Olema Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other endocrine-driven cancers, with its lead drug palazestrant in two Phase 3 tri...
Executive/Board Changes
Olema Pharmaceuticals CFO Departs; CEO Assumes Interim Role
Neutral
Jan 30, 2026
On January 30, 2026, Olema Pharmaceuticals, Inc. announced that Chief Operating and Financial Officer Shane Kovacs departed the company on that date to pursue new opportunities, though he will remain as a consultant through August 1, 2026 under a ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.